OrbiMed’s Incyte INCY Stock Holding History

OrbiMed’s Portfolio INCY Stock Details INCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-70,000	Closed	-$3.54M	–	145
2013 Q4	$3.54M	Buy	+70,000	New	+$3.05M	0.05%	104

Other funds holding INCY

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

OrbiMed's INCY Position: Q1 2020 in Review

OrbiMed sold out of Incyte (INCY) in Q1 2020, closing a stake of 59,500 shares — an estimated $5.2M sold.

OrbiMed first reported a position in INCY in Q2 2013 and held it in 20 quarters. The position peaked at $307M in Q4 2015. 491 funds tracked by Wall St. Rank hold INCY as of Q1 2020.

OrbiMed reported no remaining Incyte position as of Q1 2020 after selling out during the quarter.
OrbiMed sold 59,500 Incyte shares in Q1 2020, an estimated $5.2M.
OrbiMed first reported a position in Incyte in Q2 2013 and held it in 20 quarters.
OrbiMed's Incyte position peaked at $307M in Q4 2015.
491 funds tracked by Wall St. Rank held Incyte as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.